Refractory pemphigus vulgaris and high‐intensity extracorporeal photopheresis: A case report

A 41‐year‐old man with oral pemphigus vulgaris (PV) presented to our clinic with a history of no response to numerous immunosuppressant agents and was referred for extracorporeal photopheresis (ECP) therapy. Although the patient underwent a high‐intensity ECP regimen for 5 months, which included two different photopheresis systems, his oral dysesthesia continued to interfere with oral intake, leading to continued weight loss and other adverse events. The intervention was associated with changes in several immune cell subpopulations without modifying the anti‐epidermal antibody titers, aligned with his poor clinical outcome. To the best of the authors' knowledge, this is the first report to examine immunophenotyping of a PV patient who was refractory to previous immunosuppression and recalcitrant to high‐intensity ECP therapy.

[1]  C. Cavallini,et al.  CD66b−CD64dimCD115− cells in the human bone marrow represent neutrophil-committed progenitors , 2022, Nature Immunology.

[2]  J. Chou,et al.  Thymopoiesis, Alterations in Dendritic Cells and Tregs, and Reduced T Cell Activation in Successful Extracorporeal Photopheresis Treatment of GVHD , 2021, Journal of Clinical Immunology.

[3]  R. Pollmann,et al.  Immunophenotyping in pemphigus reveals a Th17/Tfh17-dominated immune response promoting desmoglein1/3-specific autoantibody production. , 2020, The Journal of allergy and clinical immunology.

[4]  David Chisanga,et al.  Early precursor T cells establish and propagate T cell exhaustion in chronic infection , 2020, Nature Immunology.

[5]  N. Dunbar,et al.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue , 2019, Journal of clinical apheresis.

[6]  R. Handgretinger,et al.  Monocytes show immunoregulatory capacity on CD4+ T cells in a human in‐vitro model of extracorporeal photopheresis , 2018, Clinical and experimental immunology.

[7]  M. Mustapa,et al.  British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017 , 2017, The British journal of dermatology.

[8]  S. Arora,et al.  Extracorporeal photopheresis: Review of technical aspects , 2017, Asian journal of transfusion science.

[9]  B. Schilling,et al.  Modulation and Apoptosis of Neutrophil Granulocytes by Extracorporeal Photopheresis in the Treatment of Chronic Graft-Versus-Host Disease , 2015, PloS one.

[10]  F. Kerdel,et al.  Pemphigus vulgaris treated with photopheresis. , 1992, Journal of the American Academy of Dermatology.

[11]  W. Macey,et al.  Treatment of autoimmune disease with extracorporeal photochemotherapy: pemphigus vulgaris--preliminary report. , 1989, The Yale journal of biology and medicine.